On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- Department of Defense halts PLAs on construction projects
- A Century of Labor History for the Brotherhood of Sleeping Car Porters
- CSX Threatens Engineers’ Jobs with New “Zero-Zero” Autopilot Technology
- SMART Education Department classes bring members together to strengthen our union
- Legacy: Edmonds Family Mourns a Loss While Celebrating a Future on the Rails
- “Organizing is our lifeblood:” Benson details the role every member plays in strengthening SMART
- UPDATE: Arrangements Announced for Brother Steve Bryant’s Celebration of Life
- Cuts to CSX Peer Training Leave New Hires Without Dedicated Mentors
- UPDATE: Arrangements Announced for Brother Dan Bonawitz’s Celebration of Life
- SMART Mobile App Flyer